Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors.

[1]  Masashi Kato,et al.  A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment , 2020, BMC cancer.

[2]  F. Pouliot,et al.  Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. , 2020, European urology oncology.

[3]  J. Pang,et al.  Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis , 2020, Prostate Cancer and Prostatic Diseases.

[4]  P. Kantoff,et al.  Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. , 2020, European urology.

[5]  H. Nakayama,et al.  An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression , 2019, The Prostate.

[6]  S. Egawa,et al.  Red Cell Distribution Width Predicts Prostate-Specific Antigen Response and Survival of Patients With Castration-Resistant Prostate Cancer Treated With Androgen Receptor Axis-Targeted Agents. , 2019, Clinical genitourinary cancer.

[7]  Meng Zhao,et al.  Role of Neutrophil to Lymphocyte Ratio or Platelet to Lymphocyte Ratio in Prediction of Bone Metastasis of Prostate Cancer. , 2019, Clinical laboratory.

[8]  N. Tinari,et al.  Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. , 2019, Breast.

[9]  T. Güngör,et al.  Can complete blood count inflammatory parameters in epithelial ovarian cancer contribute to prognosis? - a survival analysis , 2019, Journal of Ovarian Research.

[10]  Y. Miyoshi,et al.  Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide , 2019, BioMed research international.

[11]  Hongchuan Jin,et al.  Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a systematic review and meta-analysis. , 2018, American journal of translational research.

[12]  P. Kantoff,et al.  Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. , 2018, European urology.

[13]  E. Scarpi,et al.  Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone , 2016, Front. Pharmacol..

[14]  T. Yamasaki,et al.  Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study , 2016, International Journal of Clinical Oncology.

[15]  M. Shiota,et al.  Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone‐sensitive prostate cancer , 2016, International journal of urology : official journal of the Japanese Urological Association.

[16]  L. Egevad,et al.  A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. , 2016, European urology.

[17]  N. Fujimoto.  Novel agents for castration‐resistant prostate cancer: Early experience and beyond , 2016, International journal of urology : official journal of the Japanese Urological Association.

[18]  Liu Yong-gang,et al.  The prognostic role of neutrophils to lymphocytes ratio and platelet count in gastric cancer: A meta-analysis. , 2015, International journal of surgery.

[19]  M. Morris,et al.  Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[21]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[22]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Tangen,et al.  The prognostic value of hemoglobin change after initiating androgen‐deprivation therapy for newly diagnosed metastatic prostate cancer , 2006, Cancer.

[24]  I. Thompson,et al.  Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894. , 2004, The Journal of urology.

[25]  J. Caro,et al.  Anemia as an independent prognostic factor for survival in patients with cancer , 2001 .

[26]  S. Albayrak,et al.  Red cell distribution width as a predictor of prostate cancer progression. , 2014, Asian Pacific journal of cancer prevention : APJCP.